Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. The device is an atrio-ventricular interval modulation therapy, meaning it uses a ...
Orchestra BioMed Holdings' AVIM product received FDA breakthrough device designation, accelerating approval and offering speculative optimism for investors. The firm is pre-revenue with significant ...
Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results